These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19071184)

  • 1. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.
    Frey SE; Newman FK; Kennedy JS; Ennis F; Abate G; Hoft DF; Monath TP
    Vaccine; 2009 Mar; 27(10):1637-44. PubMed ID: 19071184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.
    Artenstein AW; Johnson C; Marbury TC; Morrison D; Blum PS; Kemp T; Nichols R; Balser JP; Currie M; Monath TP
    Vaccine; 2005 May; 23(25):3301-9. PubMed ID: 15837236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
    Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
    Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial.
    Kim SH; Yeo SG; Jang HC; Park WB; Lee CS; Lee KD; Kim HB; Kim NJ; Kim YT; Jee Y; Cho H; Oh MD; Choe KW
    J Infect Dis; 2005 Sep; 192(6):1066-70. PubMed ID: 16107961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-related effects of smallpox vaccine.
    Frey SE; Newman FK; Cruz J; Shelton WB; Tennant JM; Polach T; Rothman AL; Kennedy JS; Wolff M; Belshe RB; Ennis FA
    N Engl J Med; 2002 Apr; 346(17):1275-80. PubMed ID: 11923489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain.
    Hsieh SM; Chen SY; Sheu GC; Hung MN; Chou WH; Chang SC; Hsu KH
    Vaccine; 2006 Jan; 24(4):510-5. PubMed ID: 16139395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
    Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
    Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent neutralizing-antibody responses to vaccinia.
    Belshe RB; Newman FK; Frey SE; Couch RB; Treanor JJ; Tacket CO; Yan L
    J Infect Dis; 2004 Feb; 189(3):493-7. PubMed ID: 14745707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
    Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
    Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial.
    Greenberg RN; Kennedy JS; Clanton DJ; Plummer EA; Hague L; Cruz J; Ennis FA; Blackwelder WC; Hopkins RJ
    Lancet; 2005 Jan 29-Feb 4; 365(9457):398-409. PubMed ID: 15680454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
    Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.
    Handley L; Buller RM; Frey SE; Bellone C; Parker S
    Expert Rev Vaccines; 2009 Jul; 8(7):841-50. PubMed ID: 19538111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.
    Kim SH; Yeo SG; Park KH; Bang JW; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
    Clin Microbiol Infect; 2007 Jan; 13(1):91-3. PubMed ID: 17184294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.
    Kennedy JS; Frey SE; Yan L; Rothman AL; Cruz J; Newman FK; Orphin L; Belshe RB; Ennis FA
    J Infect Dis; 2004 Oct; 190(7):1286-94. PubMed ID: 15346340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
    N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
    Kennedy JS; Gurwith M; Dekker CL; Frey SE; Edwards KM; Kenner J; Lock M; Empig C; Morikawa S; Saijo M; Yokote H; Karem K; Damon I; Perlroth M; Greenberg RN
    J Infect Dis; 2011 Nov; 204(9):1395-402. PubMed ID: 21921208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.
    Monath TP; Caldwell JR; Mundt W; Fusco J; Johnson CS; Buller M; Liu J; Gardner B; Downing G; Blum PS; Kemp T; Nichols R; Weltzin R
    Int J Infect Dis; 2004 Oct; 8 Suppl 2():S31-44. PubMed ID: 15491873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.